Thirdly, given the present complete-matching literature, we were unable to draw a firm conclusion for optimal treatment regimen in HER2-positive BC with LM from nonrandomized controlled studies or case report carefully selected by clinicians with selection bias. The gene discussed is ERBB2; the disease is breast cancer.